Application of insulin degludec/insulin aspart injection combined with liraglutide in patients with type 2 diabetes mellitus with poor glycemic control
Objective:To investigate the application of insulin degludec/insulin aspart injection combined with liraglutide in patients with type 2 diabetes mellitus with poor blood glucose control.Methods:Ninety-two patients with type 2 diabetes mellitus with poor blood glucose control in our hospital from June 2022 to June 2023 were selected and randomly divided into the control group and the observation group(n=46).They were treated with insulin degludec/insulin aspart injection or insulin degludec/insulin aspart injection combined with liraglutide,respectively.After 4 weeks of treatment,the levels of 2-hour post-load-glucose(2hPG),fasting blood glucose(FPG),and fasting insulin were detected by an automatic biochemical analyzer.The level of hemoglobin A1c(HbA1c)was detected by an automatic glycosylated hemoglobin analyzer.Results:After treatment,the levels of FPG,2hPG,and HbA1c in the two groups were significantly decreased,and the observation group was significantly lower than the control group(P<0.05).The average time of blood glucose reaching the standard in the observation group was significantly shorter than in the control group(P<0.05).After treatment,HOMA-β levels of the two groups were significantly increased and the levels of HOMA-IR decreased(P<0.05).Also,the changes in the observation group were significantly higher than those in the control group(P<0.05).However,there is no significant difference in the overall incidence of adverse reactions between the two groups(P>0.05).Conclusion:Insulin degludec/insulin aspart injection combined with liraglutide can rapidly reduce the blood sugar level of patients with type 2 diabetes,improve the insulin function of patients,and do not increase the incidence of hypoglycemia,with high safety.
Type 2 diabetes mellitusPoor blood glucose controlInsulin degludec/insulin aspart injectionLiraglutide